What Has Been the Progress and Growth of the Plasmid DNA Manufacturing Market in Recent Years?
The plasmid dna manufacturing market has seen considerable growth due to a variety of factors.
• The plasmid DNA manufacturing market has experienced exponential growth in recent years. It will rise from $2.34 billion in 2024 to $2.9 billion in 2025, with a compound annual growth rate (CAGR) of 23.9%.
This growth is driven by the use of plasmid DNA in industrial processes, the creation of genetically modified organisms, production of monoclonal antibodies, and applications in bioremediation and microbiome studies.
How Does the Forecast Look for the Plasmid DNA Manufacturing Market?
The plasmid dna manufacturing market is expected to maintain its strong growth trajectory in upcoming years.
• The plasmid DNA manufacturing market is expected to see exponential growth, reaching $6.78 billion by 2029, with a CAGR of 23.6%.
This growth is attributed to the increasing use of plasmid DNA in developing DNA vaccines, antibody-drug conjugates, personalized therapies, and cancer treatments. Key trends include licensing agreements, customized solutions, cost reduction strategies, high-throughput screening, and scalable manufacturing solutions.
What Are The Leading Drivers Of Growth In The Plasmid DNA Manufacturing Market?
The increased adoption of gene therapy is anticipated to drive the expansion of the plasmid DNA manufacturing market. Gene therapy, a treatment procedure that modifies or manipulates an individual's genes for disease treatment or prevention, is gaining traction. This is attributed to progress in genetic engineering technologies, increased funding for research and development, successful clinical trials, and the rising occurrence of genetic disorders. These points underscore the potential of gene therapy to provide lasting or permanent solutions. Plasmid DNA manufacturing plays a critical role in gene therapy by producing the vectors that deliver therapeutic genes into cells, enabling the addressing of genetic disorders. For example, data from the American Society of Gene & Cell Therapy, a non-profit medical and scientific organization based in the US, indicates a 10% growth in gene therapies in Phase III clinical trials in Q3 2023, the first quarterly increment since Q3 2022. Therefore, the escalating adoption of gene therapy is fueling the plasmid DNA manufacturing market's growth.
How Are The Segments Defined Within The Global Plasmid DNA Manufacturing Market?
The plasmid DNA manufacturing market covered in this report is segmented –
1) By Grade: Research And Development Grade, Good Manufacturing Practice (GMP) Grade
2) By Development Phase: Pre-Clinical Therapeutics, Clinical Therapeutics, Marketed Therapeutics
3) By Disease: Infectious Disease, Cancer, Genetic Disorder, Other Diseases
4) By Application: Deoxyribonucleic Acid (DNA) Vaccines, Cell And Gene Therapy, Immunotherapy, Other Applications
Subsegments:
1) By Research And Development Grade: Small-scale Plasmid DNA Production, Preclinical Research Plasmid DNA
2) By Good Manufacturing Practice (GMP) Grade: Clinical Trial Material Production, Commercial-Scale Plasmid DNA Production
Pre-Book The Plasmid DNA Manufacturing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
Which Emerging Market Trends Are Altering The Plasmid DNA Manufacturing Industry?
Key players in the plasmid DNA manufacturing sector are adopting state-of-the-art bioprocessing technologies to boost effectiveness, scalability, and product quality. The focus of these breakthroughs is to simplify manufacturing protocols, lower costs, and also ensure the produced plasmid DNA adheres to strict regulatory benchmarks necessary for therapeutic uses. For instance, Charles River Laboratories, a pharmaceutical entity based in the US, rolled out the eXpDNA platform in January 2023. The aim was to simplify the production and purification processes of superior-grade plasmid DNA. The platform adopts cutting-edge bioprocessing technologies, scale-up production strategies, and strict quality assurance measures to generate plasmid DNA that satisfies the rigorous needs for therapeutic and clinical uses. The eXpDNA platform finds widespread use in DNA vaccine formulation, gene therapy, and other bio-pharma applications that require high yield, purity, and uniformity.
Who Are the Key Players In The Plasmid DNA Manufacturing Market?
Major companies operating in the plasmid DNA manufacturing market are:
• Thermo Fisher Scientific Inc.
• Eurofins Genomics LLC
• Catalent Inc.
• Charles River Laboratories
• Recipharm AB
• Kaneka Corp.
• Genscript Biotech Corporation
• Aldevron LLC
• Genewiz
• OriGene Technologies
• Celonic AG
• Creative Biogene
• Cellectis
• Synbio Technologies
• VectorBuilder Inc.
• Altogen Biosystems
• Addgene
• Andelyn Biosciences
• AGC Biologics
• VGXI
• BioCat GmbH
• GeneCopoeia
• PlasmidFactory GmbH & Co. KG
• Akron Biotech
• PackGene Biotech lnc.
What Is The Most Dominant Region In The Plasmid DNA Manufacturing Market?
North America was the largest region in the plasmid DNA manufacturing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the plasmid DNA manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
